论文部分内容阅读
目的探讨替比夫定对失代偿期乙肝肝硬化患者近期疗效及用药安全性。方法 136例失代偿期乙肝肝硬化患者,采用简单抽样法随机分成替比夫定组(A组)和常规治疗组(B组),各68例。比对两组患者治疗前后肝功能Child-Pugh分级情况,记录其用药后疗效及不良反应发生率。结果 1治疗后,A、B两组Child-Pugh评分均较治疗前明显降低,其中A组为(5.1±0.3)分,与B组的(7.8±0.5)分对比差异具有统计学意义(P<0.05);2 A组总有效率为97.1%,同B组的70.6%对比差异具有统计学意义(P<0.05);3 A组给药后出现头痛、皮疹、疲劳等轻微反应者各1例,不良反应发生率为4.4%,其余患者均无明显不良反应发生,对比差异无统计学意义(P>0.05)。结论对失代偿期乙肝肝硬化患者予以常规疗法联合替比夫定方案,疗效显著,不良反应发生率较低,值得临床推广。
Objective To explore the short-term efficacy and safety of telbivudine in patients with decompensated hepatitis B cirrhosis. Methods 136 patients with decompensated hepatitis B cirrhosis were randomly divided into telbivudine group (group A) and conventional treatment group (group B), 68 cases in each group. The results of Child-Pugh classification of liver function before and after treatment were compared between the two groups, and the curative effect and incidence of adverse reactions were recorded after treatment. Results After treatment, the Child-Pugh scores in group A and group B were significantly lower than those before treatment, in which group A was (5.1 ± 0.3) points, compared with group B (7.8 ± 0.5), the difference was statistically significant (P <0.05). The total effective rate in group A was 97.1%, which was significantly lower than that in group B (70.6%) (P <0.05). In group A, there were 1 Cases, the incidence of adverse reactions was 4.4%, the remaining patients were no significant adverse reactions, the difference was not statistically significant (P> 0.05). Conclusions The conventional therapy combined with telbivudine regimen in patients with decompensated hepatitis B cirrhosis has significant curative effect and low incidence of adverse reactions, which is worthy of clinical promotion.